Revascularization Using DES in Infrapopliteal Disease: Meta-Analysis and Change of Paradigm?

Peripheral vascular disease (PVD) has been under-studied and under-recognized in comparison with ischemic heart disease and stroke, despite its well-known impact on quality of life and its associated morbidity and mortality. According to a systematic review, it was estimated that in 2015 about 238 million people globally had PVD. This number is on the rise.

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

Percutaneous treatment of infrapopliteal disease has shown benefit. However, the best alternative (balloon angioplasty, drug-eluting balloon or conventional/drug-eluting stent implantation) is still unclear, so ongoing research is currently focusing on finding an answer to that question.

The aim of this work, recently published in the Journal of the Society for Cardiovascular Angiography & Interventions, was to perform a systematic review and meta-analysis of randomized studies to evaluate the efficacy and safety of drug-eluting stent (DES) implantation (everolimus/sirolimus/paclitaxel) compared with a control group of endovascular revascularization (plain old balloon angioplasty, drug-coated balloon, stent), for infrapopliteal disease. The primary outcome (PO) was primary patency and the secondary outcomes (SO) were target lesion revascularization (TLR), major limb amputation, and all-cause mortality.

Researchers included 9 randomized studies published in 2007 or after, with a total of 945 patients, whose age range was between 68 and 75 years; most patients were men, with a prevalence of diabetes of 50 to 82%. Follow-up was between a minimum of 6 months and a maximum of 48 months, and, in general, invasive angiography was the method used to assess patency.

Read also: EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation.

Patients treated with DES had a significant increase in primary patency compared with the control group (hazard ratio [HR]: 2.58, 95% confidence interval [CI]: 1.49-4.49; p = 0.0008). When analyzing the SOs, a significant reduction in TLR (HR: 0.48, 95% CI: 0.33-0.68; p <0.0001) was observed, without significant differences in major limb amputation (HR: 0.87, 95% CI: 0.56-1.36; p = 0.28) or all-cause mortality (HR: 0.64, 95% CI: 0.40-1.04; p = 0.95).

Conclusions

The results of this meta-analysis showed better primary patency and lower TLR in patients who underwent infrapopliteal angioplasty with DES compared with conventional revascularization. This benefit in favor of DES use is a similar effect to what was previously observed regarding coronary disease.

Previously, stent revascularization was only reserved as a bailout strategy after balloon angioplasty. This systematic review has some limitations due to the heterogeneity of the studies included and the small number of patients. Based on these results, should we consider the evidence as sufficient to trigger a change in the paradigm for revascularization in infrapopliteal disease?

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Drug-Eluting Stents Versus Conventional Endovascular Therapies in Symptomatic Infrapopliteal Peripheral Artery Disease: A Meta-analysis.

Source: Changal, Khalid et al. Drug-Eluting Stents Versus Conventional Endovascular Therapies in Symptomatic Infrapopliteal Peripheral Artery Disease: A Meta-analysis. Journal of the Society for Cardiovascular Angiography & Interventions, Volume 1, Issue 2, 100024. https://doi.org/10.1016/j.jscai.2022.100024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...